Comprehensive Analysis of Anamorelin (DB06645): A Ghrelin Receptor Agonist for Cancer Anorexia-Cachexia Syndrome

Executive Summary

Anamorelin is a first-in-class, orally bioavailable, small-molecule, selective ghrelin receptor agonist developed to address the profound unmet medical need of cancer anorexia-cachexia syndrome (CACS).[1] CACS is a debilitating multifactorial condition characterized by loss of appetite and a progressive wasting of skeletal muscle and adipose tissue, which is associated with poor prognosis, reduced tolerance to cancer therapies, and diminished quality of life.[4] The therapeutic rationale for Anamorelin is rooted in its ability to mimic the physiological actions of ghrelin, an endogenous peptide often termed the "hunger hormone".[7]

The core mechanism of Anamorelin involves potent and specific stimulation of the growth hormone secretagogue receptor type 1a (GHSR-1a).[7] This action initiates a dual-pronged physiological response. Centrally, it stimulates hypothalamic pathways to increase appetite and food intake (orexigenic effect). Concurrently, it triggers the pulsatile release of growth hormone (GH) from the pituitary gland, which in turn stimulates hepatic production of insulin-like growth factor-1 (IGF-1). This activation of the GH/IGF-1 axis promotes anabolism, leading to the synthesis of muscle protein and an increase in lean body mass (LBM).[7]

Pivotal clinical evidence for Anamorelin is derived from the global, Phase III ROMANA 1 and ROMANA 2 trials. These studies unequivocally demonstrated that Anamorelin treatment in patients with non-small cell lung cancer (NSCLC) and cachexia resulted in a statistically significant increase in LBM compared to placebo over 12 weeks. However, the program failed to meet its co-primary functional endpoint, showing no significant improvement in handgrip strength (HGS).[12]

This split verdict on the primary endpoints—demonstrating an anabolic effect without a corresponding functional gain—has led to a stark global regulatory dichotomy that defines the drug's current status. Japan's Pharmaceuticals and Medical Devices Agency (PMDA), weighing the significant unmet need and the positive LBM and appetite data, granted approval for Anamorelin (marketed as Adlumiz) for CACS in several cancer types.[6] In stark contrast, the European Medicines Agency (EMA) refused marketing authorisation, citing the LBM effect as "marginal" and emphasizing the lack of proven benefit on muscle function or patient quality of life, concluding that the drug's benefits did not outweigh its risks.[14] In the United States, Anamorelin remains an investigational agent.[2]

This report provides an exhaustive analysis of Anamorelin, detailing its molecular profile, pharmacology, clinical trial data, and safety profile. It critically examines the divergent regulatory interpretations, which underscore the fundamental challenges in defining clinically meaningful endpoints for cachexia. Anamorelin's development journey serves as a landmark case study, highlighting the evolving standards for therapeutic approval in supportive oncology and the critical need for interventions that can translate anabolic gains into tangible functional improvements for patients.

Molecular Profile and Physicochemical Characteristics

Anamorelin is a synthetic, non-peptidic small molecule designed to mimic the N-terminal active core of the endogenous hormone ghrelin.[1] Its development as an orally active agent represents a significant advancement over native ghrelin, which is limited by a short half-life and the need for parenteral administration.[7]

Chemical Identity and Nomenclature

Anamorelin is identified by a consistent set of chemical names and development codes across global databases and clinical trials.

• Generic Name: Anamorelin. The drug is often studied and formulated as its hydrochloride salt, Anamorelin Hydrochloride.[15]
• IUPAC Name: The systematic name for the free base is 2-amino-N-piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide.[1]
• Synonyms and Codes: During its development, Anamorelin was known by several codes, including ONO-7643, RC-1291, and ST-1291.[1] In Japan, where it is approved, it is marketed under the trade name Adlumiz.[8]

Structural and Formulaic Data

Anamorelin's structure is that of a complex dipeptide derivative, which confers its ability to bind to the ghrelin receptor.[15]

• Type: It is classified as a Small Molecule and a Synthetic Organic compound.[15]
• Molecular Formula: The chemical formula for the free base is C31​H42​N6​O3​.[1]
• Molecular Weight: The average molecular weight is 546.716 g/mol, with a monoisotopic mass of 546.331839236 Da.[1]
• Structure Representation: Its structure is defined by standard chemical notations:
• SMILES: CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N.[1]
• InChIKey: VQPFSIRUEPQQPP-MXBOTTGLSA-N.[1]

Key Identifiers

The compound is uniquely tracked in major chemical and drug databases through the following identifiers:

• DrugBank ID: DB06645.[1]
• CAS Number: 249921-19-5.[1]
• UNII (Unique Ingredient Identifier): DD5RBA1NKF.[1]

Physicochemical Properties

The physicochemical properties of Anamorelin dictate its formulation, absorption, and distribution characteristics. It typically presents as a white to beige powder.[23] Its solubility profile is a key consideration for its oral formulation; it has very low aqueous solubility but is soluble in various organic solvents such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and ethanol.[15] The molecule's moderate lipophilicity and structural characteristics influence its "druglikeness," where it satisfies most, but not all, of the criteria in Lipinski's Rule of Five, primarily due to its molecular weight exceeding 500 Da.[15]

Table 1: Key Physicochemical Properties of Anamorelin

Property	Value	Source(s)
IUPAC Name	2-amino-N-piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide	1
Molecular Formula	C31​H42​N6​O3​	1
Molecular Weight	546.7 g/mol	1
CAS Number	249921-19-5	1
InChIKey	VQPFSIRUEPQQPP-MXBOTTGLSA-N	1
Water Solubility	0.0103 mg/mL	15
logP	2.36 - 2.86	15
pKa (Strongest Acidic)	12.7	15
pKa (Strongest Basic)	8.34	15
Polar Surface Area	114.77 A˚2	15
Rotatable Bond Count	9	15
Hydrogen Bond Donors	3	15
Hydrogen Bond Acceptors	5	15
Rule of Five Violations	1 (Molecular Weight > 500)	15

Pharmacology: Mechanism of Action and Pharmacodynamic Effects

Anamorelin's therapeutic activity is derived from its function as a potent and selective ghrelin mimetic. It targets the same receptor as endogenous ghrelin to produce anabolic and appetite-stimulating effects that directly counteract the primary symptoms of CACS.

Ghrelin Receptor Agonism

Anamorelin's primary molecular target is the Growth Hormone Secretagogue Receptor Type 1a (GHSR-1a).[1] This G protein-coupled receptor is the natural binding site for ghrelin and is expressed in key areas of the central nervous system, including the hypothalamus and pituitary gland, as well as in peripheral tissues.[4]

• Binding Affinity and Potency: Anamorelin demonstrates high affinity for GHSR-1a, with a reported binding affinity constant (Ki​) of 0.70 nM and a half-maximal effective concentration (EC50​) for receptor activation of 0.74 nM.[7] This potency is comparable to that of native ghrelin, enabling it to effectively stimulate the receptor at therapeutic concentrations.[7] In vitro studies confirm that Anamorelin acts as a full agonist with no detectable antagonistic properties.[7]
• Selectivity: The drug exhibits a high degree of selectivity for the ghrelin receptor. When screened against a large panel of over 100 other receptors, ion channels, transporters, and enzymes, Anamorelin showed minimal off-target activity. While some binding to the tachykinin neurokinin 2 (NK2) receptor was observed, subsequent functional assays confirmed no agonist or antagonist activity at this site, underscoring its specific mechanism of action.[25]

Endocrine and Metabolic Impact

By activating GHSR-1a, Anamorelin initiates a cascade of neuroendocrine and metabolic effects that form the basis of its clinical utility.

• Stimulation of the GH/IGF-1 Axis: The most prominent pharmacodynamic effect of Anamorelin is the robust stimulation of the somatotropic axis. Activation of GHSR-1a in the pituitary gland and hypothalamus leads to a significant, pulsatile release of Growth Hormone (GH).[7] In clinical studies, peak GH levels are observed approximately one hour after oral administration.[4] This surge in circulating GH acts on the liver, stimulating the synthesis and secretion of Insulin-like Growth Factor-1 (IGF-1) and its primary carrier protein, Insulin-like Growth Factor-Binding Protein 3 (IGFBP-3).[10]
• Anabolic Effects: The elevated levels of both GH and IGF-1 are the principal mediators of Anamorelin's anabolic properties. These hormones act directly on muscle tissue to stimulate muscle protein synthesis and inhibit protein degradation, thereby promoting an increase in lean body mass (LBM).[10] This anabolic drive is central to the drug's potential to reverse the muscle wasting characteristic of cachexia.
• Orexigenic (Appetite-Stimulating) Effects: Anamorelin mimics ghrelin's well-established role as a powerful appetite stimulant. It crosses the blood-brain barrier and acts on GHSR-1a expressed on neurons in key appetite-regulating centers of the brain, such as the arcuate nucleus of the hypothalamus.[1] This stimulation is believed to increase the activity of orexigenic mediators like neuropeptide Y, leading to increased feelings of hunger, enhanced appetite, and greater food intake.[4] Access to central reward areas of the brain may also contribute to its potent appetite-enhancing effects.[7]
• Anti-inflammatory Potential: Chronic inflammation is a key pathological driver of CACS, with pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contributing to muscle and fat tissue breakdown. Endogenous ghrelin has known anti-inflammatory properties. By mimicking ghrelin, Anamorelin may help to downregulate the expression of these catabolic cytokines, providing an additional mechanism to alleviate the cachectic state.[4]
• Selectivity of Endocrine Effects: Pharmacodynamic studies in healthy volunteers have confirmed that Anamorelin's hormonal effects are highly specific to the GH axis. Even at supratherapeutic doses, it does not meaningfully alter the levels of other anterior pituitary hormones, including prolactin, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH), nor does it directly impact cortisol levels.[16]

The pharmacology of Anamorelin is uniquely tailored to the complex pathophysiology of CACS. The syndrome is defined by two core problems: anorexia, which leads to reduced caloric intake, and a hypermetabolic, hypercatabolic state that actively breaks down muscle tissue, a process that cannot be reversed by nutritional support alone.[4] Anamorelin's mechanism addresses both of these pillars simultaneously. Its central action on the hypothalamus directly combats anorexia by stimulating appetite.[4] Concurrently, its stimulation of the GH/IGF-1 axis provides a powerful anabolic signal to counteract muscle wasting.[7] This dual-pronged approach represents a significant conceptual advantage over earlier therapeutic strategies, such as progestins (e.g., megestrol acetate), which primarily stimulate appetite and lead to gains in fat mass, or corticosteroids, which have short-lived effects and significant long-term toxicities.[31] The potential for an additional, anti-inflammatory effect further strengthens its therapeutic rationale.[10] This comprehensive mechanism, targeting multiple facets of the syndrome, explains the considerable scientific and clinical interest in Anamorelin's development as a potential first-in-class therapy for CACS.[3]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Anamorelin is characterized by rapid oral absorption, extensive tissue distribution, and primary metabolism via the CYP3A4 enzyme system. These properties make it suitable for once-daily oral dosing but also introduce a significant potential for drug-drug interactions.

Absorption and Distribution

• Route and Bioavailability: Anamorelin is formulated for oral administration and is rapidly absorbed from the gastrointestinal tract.[1] Pharmacokinetic studies have reported a median time to maximum plasma concentration ( Tmax​) ranging from 0.5 to 1.88 hours across different study populations, indicating a swift onset of systemic exposure.[5] The absolute oral bioavailability of Anamorelin has been determined to be approximately 37.0%.[28]
• Food Effect: The absorption of Anamorelin is significantly impacted by the presence of food. When administered two hours after a meal, the maximum plasma concentration (Cmax​) and the total drug exposure (area under the plasma concentration-time curve, AUC) were reduced by 69% and 51%, respectively, compared to administration in a fasted state.[7] This pronounced negative food effect necessitates that the drug be taken on an empty stomach, at least one hour before a meal, to ensure adequate and consistent absorption.[6]
• Distribution: Anamorelin exhibits extensive distribution into body tissues, as indicated by its large apparent volume of distribution (Vd​) of 583.88 L.[28] In human plasma, it is highly bound to proteins, with a binding rate of 97.3% to 98.3%. The primary binding protein is α1-acid glycoprotein, a plasma protein often elevated in inflammatory states such as cancer.[28]

Metabolism and Excretion

• Primary Metabolic Pathway: Anamorelin undergoes extensive hepatic metabolism. The primary enzyme responsible for its biotransformation is the cytochrome P450 3A4 (CYP3A4) isoenzyme.[7] The major identified metabolites are a monoxidized product (M4) and an N-demethylated product (M6).[28] Ongoing in-vitro studies using human liver microsomes are further characterizing the complete metabolic profile of the drug.[21]
• Drug-Drug Interactions (DDIs): The drug's heavy reliance on CYP3A4 for clearance creates a clinically significant potential for drug-drug interactions, a critical consideration in oncology patients who often receive polypharmacy.
• CYP3A4 Inhibitors: Concomitant administration with strong CYP3A4 inhibitors, such as the antifungal agent ketoconazole, results in a substantial increase in Anamorelin exposure. Studies in healthy volunteers showed that ketoconazole increased Anamorelin Cmax​ and AUC by approximately 3-fold.[7] This interaction could increase the risk of adverse effects.
• CYP3A4 Inducers: Conversely, co-administration with strong CYP3A4 inducers, such as the antibiotic rifampin, leads to a significant reduction in Anamorelin exposure. Rifampin decreased Anamorelin Cmax​ by approximately 55% and AUC by approximately 67%.[33] This interaction could compromise the drug's efficacy.
• Excretion: Following metabolism, Anamorelin and its metabolites are eliminated predominantly via the biliary-fecal route. Studies using radiolabeled Anamorelin showed that approximately 92% of the dose was recovered in the feces, with only 8% recovered in the urine.[5] This excretion pattern suggests that impaired renal function is unlikely to have a major impact on the drug's pharmacokinetics.[7]
• Half-Life: The terminal elimination half-life (t1/2​) of Anamorelin is consistently reported to be in the range of 6 to 9 hours.[5] This half-life supports a convenient once-daily dosing regimen.

The pharmacokinetic profile of Anamorelin presents both a key advantage and a significant clinical liability. Its oral bioavailability and half-life of approximately 7 hours make it a practical and viable option for outpatient therapy, overcoming the major limitations of native ghrelin, which requires intravenous administration and has a very short half-life of about 30 minutes.[7] This was a crucial step in translating the therapeutic potential of ghrelin agonism into a feasible clinical treatment. However, the drug's near-total dependence on a single, highly inducible, and inhibitable metabolic pathway—CYP3A4—is a considerable challenge.[33] Cancer patients are frequently prescribed a multitude of medications, including anti-emetics, antifungals, antibiotics, and targeted therapies, many of which are potent modulators of CYP3A4. This creates a high-risk environment for unpredictable drug exposure, potentially leading to sub-therapeutic efficacy when co-administered with inducers or increased toxicity when given with inhibitors. This significant drug-drug interaction potential represents a critical aspect of risk management, necessitating careful review of concomitant medications and likely contributed to the stringent post-marketing surveillance requirements mandated by Japanese regulators.[6]

Table 2: Summary of Pharmacokinetic Parameters of Anamorelin

Parameter	Value / Description	Source(s)
Tmax​ (Time to Peak Concentration)	0.5 - 1.88 hours	5
Terminal Half-life (t1/2​)	6 - 9 hours	5
Absolute Bioavailability	37.0%	28
Volume of Distribution (Vd​)	583.88 L	28
Plasma Protein Binding	97.3% - 98.3%	28
Primary Metabolism Route	Hepatic, via CYP3A4	7
Primary Excretion Route	92% Fecal / 8% Renal	5
Impact of Food on AUC / Cmax​	↓ 51% / ↓ 69%	7
Impact of Strong CYP3A4 Inhibitors on AUC / Cmax​	↑ ~3-fold / ↑ ~3-fold	7
Impact of Strong CYP3A4 Inducers on AUC / Cmax​	↓ ~67% / ↓ ~55%	33

Clinical Efficacy in Cancer Anorexia-Cachexia Syndrome (CACS)

The clinical development program for Anamorelin in CACS culminated in two large, pivotal Phase III trials. While earlier phase studies provided strong proof-of-concept, the results of the Phase III program presented a complex picture of efficacy that has been subject to different interpretations by global regulatory bodies.

Early Phase Clinical Development

Phase I studies conducted in healthy volunteers successfully characterized the drug's pharmacodynamic profile. These trials demonstrated that oral administration of Anamorelin led to dose-dependent increases in GH and IGF-1 levels and corresponding increases in body weight, all while maintaining a favorable safety and tolerability profile.[5]

Following this, Phase II trials provided the first evidence of efficacy in the target patient population. These randomized, placebo-controlled studies, conducted in patients with various types of cancer and cachexia, confirmed that Anamorelin treatment could produce statistically significant and clinically meaningful benefits. Over short treatment periods, Anamorelin was shown to increase body weight, improve LBM, and favorably alter metabolic markers. Importantly, these trials also demonstrated improvements in patient-reported outcomes, including a significant increase in appetite.[2] These positive results provided a strong rationale to proceed with the large-scale Phase III program.

The ROMANA Phase III Program: A Critical Analysis

The cornerstone of Anamorelin's clinical evidence package consists of two identically designed, global, Phase III trials: ROMANA 1 (NCT01387269) and ROMANA 2 (NCT01387282).[13]

• Study Design: Both were randomized (2:1, Anamorelin to placebo), double-blind, placebo-controlled, multicenter studies. They enrolled patients with unresectable Stage III or IV non-small cell lung cancer (NSCLC) who had cachexia, defined as either ≥5% involuntary weight loss within the previous 6 months or a body mass index (BMI) <20 kg/m². A total of 484 patients were enrolled in ROMANA 1 and 495 in ROMANA 2. Participants received either 100 mg of Anamorelin or a matching placebo orally once daily for a period of 12 weeks.[13]
• Co-Primary Endpoints: The studies were designed with two co-primary efficacy endpoints, both of which needed to be met for the trials to be considered successful: (1) the median change from baseline in lean body mass (LBM), as measured by dual-energy X-ray absorptiometry (DEXA), and (2) the median change from baseline in handgrip strength (HGS).[13]
• Efficacy Results - A Split Verdict: The results of the ROMANA program were notable for their divergence on the two primary endpoints.
• Lean Body Mass (LBM): Anamorelin demonstrated a robust and highly statistically significant effect on LBM in both trials, successfully meeting this co-primary endpoint. In ROMANA 1, patients in the Anamorelin group experienced a median increase of 0.99 kg in LBM, whereas the placebo group had a median loss of 0.47 kg (p<0.0001). Similarly, in ROMANA 2, the Anamorelin group gained a median of 0.65 kg of LBM, compared to a median loss of 0.98 kg in the placebo group (p<0.0001).[13]
• Handgrip Strength (HGS): In stark contrast to the LBM results, Anamorelin FAILED to demonstrate any benefit on muscle function as measured by HGS. In both ROMANA 1 and ROMANA 2, there was no statistically significant difference in the change in HGS between the Anamorelin and placebo arms.[13]
• Secondary Endpoints: Anamorelin did show statistically significant benefits in key secondary endpoints. Patients treated with Anamorelin experienced a significant increase in total body weight compared to placebo. Furthermore, they reported a meaningful improvement in anorexia and cachexia-related symptoms, as measured by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) Anorexia/Cachexia Subscale (A/CS).[12]

Table 3: Efficacy Outcomes of the ROMANA 1 & 2 Phase III Trials

Endpoint	Trial	Anamorelin Group (Median Change)	Placebo Group (Median Change)	p-value
Lean Body Mass (kg)	ROMANA 1	+0.99	-0.47	<0.0001
	ROMANA 2	+0.65	-0.98	<0.0001
Handgrip Strength (kg)	ROMANA 1	-1.10	-1.58	0.15
	ROMANA 2	-1.49	-0.95	0.65
Body Weight (kg)	ROMANA 1	+2.20	+0.14	<0.0001
	ROMANA 2	+0.75	-0.96	<0.0001

Note: Data for Body Weight in ROMANA 1 and 2 are presented as average change, as reported in.[41]

Post-Hoc Analyses and Subgroup Insights

Subsequent post-hoc analyses of the pooled data from the ROMANA trials have provided additional context. These analyses suggest that the anabolic benefits of Anamorelin may be particularly pronounced in patients with more severe disease characteristics at baseline. For instance, patients with a higher degree of systemic inflammation (as measured by the modified Glasgow Prognostic Score), a lower baseline BMI (<20 kg/m²), or a history of more substantial weight loss (≥10%) appeared to derive the greatest benefit in terms of LBM and body weight gain.[12]

The results of the ROMANA program created a central conundrum for the clinical and regulatory evaluation of Anamorelin. The drug unequivocally demonstrated its intended anabolic effect, successfully building lean tissue as confirmed by the highly significant LBM data.[13] This fulfilled the promise of its mechanism of action via the GH/IGF-1 axis. However, the consistent failure to show that this newly accrued muscle mass translated into improved physical function, as measured by HGS, raised a critical question about the drug's overall clinical benefit.[13] This disconnect between an increase in muscle mass and an improvement in muscle strength became the focal point of regulatory debate. It suggests that the pathophysiology of cancer cachexia is more complex than simple muscle protein loss; it likely involves other factors such as mitochondrial dysfunction, neuromuscular impairment, or persistent inflammation that an anabolic stimulus alone cannot overcome. The ROMANA results have had a profound impact on the field, challenging the long-held assumption that simply increasing muscle mass will automatically lead to better function. This has informed subsequent clinical trial design for cachexia, emphasizing the need for co-primary endpoints that assess both body composition and a clinically meaningful measure of physical function or patient-reported quality of life.

Exploration in Other Indications

Beyond cancer cachexia, the anabolic and metabolic properties of Anamorelin have prompted investigation into its potential use for other conditions characterized by muscle and bone loss, most notably age-related sarcopenia and osteosarcopenia.

Sarcopenia and Osteosarcopenia

Sarcopenia, the age-related loss of muscle mass and function, and osteosarcopenia, the concurrent loss of both muscle and bone, represent a significant cause of frailty and morbidity in the elderly population.[35] Given Anamorelin's mechanism of stimulating the GH/IGF-1 axis, which is known to decline with age and is crucial for musculoskeletal health, the drug was identified as a potential therapeutic candidate for this condition.[35]

A pilot, randomized, double-blind, placebo-controlled trial was conducted to evaluate the effects of 100 mg/day of Anamorelin over one year in 26 older adults with osteosarcopenia.[35]

• Results on Muscle Mass: The study's primary endpoint of change in muscle mass, as measured by the D3-creatine dilution method, was not met. Anamorelin did not produce a statistically significant increase in muscle mass or in LBM as measured by DEXA, although there were non-significant trends favoring the treatment group. The investigators attributed the lack of statistical significance primarily to the small sample size and the inherent variability in the measurement techniques.[35] A small but statistically significant increase in total body weight was observed, providing some support for a positive anabolic effect.[35]
• Positive Signals on Function and Bone: Despite the negative result on the primary endpoint, the trial revealed several intriguing positive signals.
• Muscle Function: Unlike in the ROMANA trials, this study showed a significant improvement in a measure of lower extremity strength. Patients receiving Anamorelin had a 20% increase in peak knee flexion torque compared to placebo (p=0.013).[42]
• Bone Metabolism: Anamorelin demonstrated a positive effect on bone formation. It significantly increased levels of serum procollagen type 1 N-terminal propeptide (P1NP), a key marker of bone formation, by 75% (p=0.006), without significantly affecting markers of bone resorption.[42]
• Endocrine Effects: As expected, treatment led to a 50% increase in serum IGF-1 levels compared to no change in the placebo group (p=0.0001).[42]

The findings from this pilot study in osteosarcopenia present a nuanced picture of Anamorelin's potential efficacy. The observation of a functional improvement (knee strength) in this population, which was absent in the much larger CACS trials, is particularly noteworthy. This difference may be attributable to the distinct underlying pathologies. The intense inflammatory and catabolic environment of cancer cachexia may blunt the ability of newly formed muscle tissue to become fully functional, whereas the more gradual decline seen in age-related sarcopenia may be more responsive to an anabolic stimulus. Furthermore, the novel finding of a positive effect on a bone formation marker is mechanistically plausible given the role of the GH/IGF-1 axis in bone health and suggests a potential dual benefit for osteosarcopenia.[42] While the study was underpowered to definitively assess effects on muscle mass, these positive signals on both muscle function and bone metabolism provide a strong rationale for conducting larger, adequately powered trials to further explore Anamorelin's role in treating age-related musculoskeletal decline.

Safety, Tolerability, and Risk Management

The safety profile of Anamorelin has been characterized through a comprehensive clinical trial program and, more recently, through extensive post-marketing surveillance in Japan. Overall, the drug has been found to be generally well-tolerated, with a predictable set of adverse effects primarily related to its mechanism of action.

Clinical Trial Safety Data

The integrated safety data from the ROMANA 1, ROMANA 2, and the ROMANA 3 extension study, which followed patients for a total of 24 weeks, form the primary basis of the drug's safety assessment.[38] In these large, placebo-controlled trials, Anamorelin demonstrated a safety profile that was broadly similar to placebo. The overall incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs of grade 3 or higher was comparable between the Anamorelin and placebo groups.[38] The rate of discontinuation due to adverse events was also similar in both arms, suggesting good tolerability over the 24-week treatment period.[38]

Key Safety Concerns and Adverse Events

While the overall incidence of adverse events was similar to placebo, specific on-target effects and other risks have been identified as important for monitoring.

• Hyperglycemia: The most common and consistent treatment-related adverse event (TRAE) associated with Anamorelin is hyperglycemia (elevated blood sugar).[39] In the ROMANA 3 extension study, drug-related hyperglycemia was reported in 1.2% of patients on Anamorelin versus none on placebo.[38] The incidence was somewhat higher in the initial 12-week trials, at approximately 4-5%.[47] This effect is a predictable consequence of stimulating the GH/IGF-1 axis, which is known to promote a state of insulin resistance.[27] While typically mild and manageable, this requires caution, particularly in patients with pre-existing diabetes or glucose intolerance.[34]
• Cardiac Risks and Conduction Disorders: A significant safety signal that has emerged, particularly from post-marketing data and regulatory warnings in Japan, is the risk of cardiac conduction abnormalities, including QT interval prolongation.[48] An analysis of the Japanese Adverse Drug Event Report (JADER) database revealed a reporting odds ratio for conduction defects that was significantly elevated for Anamorelin. The median time to onset for these events was 13 days after treatment initiation.[49] While most reported cases resolved, this risk necessitates careful patient selection and monitoring.
• Gastrointestinal Disturbances: Nausea is another frequently reported TRAE. Data from real-world clinical use in Japan show an incidence of 2.6% for treatment-related nausea.[50] Other mild gastrointestinal disturbances have also been noted.[46]

Table 4: Incidence of Common Treatment-Related Adverse Events (TRAEs)

Adverse Event	Incidence in ROMANA Trials (Anamorelin %)	Incidence in ROMANA Trials (Placebo %)	Incidence in Japanese Post-Marketing Surveillance (%)
Hyperglycemia	~1.2% - 5.3%	0.0%	3.9%
Nausea	Not specified	Not specified	2.6%
Conduction Disorders	Not specified	Not specified	1.1%
Hepatic Impairment	Not specified	Not specified	1.2%

Note: Data for ROMANA trials are from [39] and.[47] Data for Japanese Post-Marketing Surveillance are from.[50]

Post-Marketing Surveillance and Risk Management Plan (RMP)

Reflecting the need for further characterization of the drug's safety profile in a real-world setting, the Japanese PMDA's approval of Anamorelin was contingent upon the implementation of a mandatory Risk Management Plan (RMP) and a comprehensive post-marketing use-results survey.[6] An interim analysis of this surveillance, including data from over 6,000 patients, was published. The results confirmed the safety profile observed in clinical trials, with hyperglycemia (3.9%) and nausea (2.6%) being the most common TRAEs. Crucially, this large-scale analysis did not identify any new or unexpected safety concerns.[50] The surveillance also provided real-world confirmation of the drug's effectiveness, showing sustained improvements in body weight and appetite over a period of up to 52 weeks.[50]

The Global Regulatory Divide: A Comparative Analysis

The clinical development of Anamorelin culminated in one of the most striking examples of divergent regulatory decision-making in modern oncology. Despite being evaluated based on a similar global data package, primarily from the ROMANA trials, the world's leading regulatory agencies arrived at opposite conclusions, creating a distinct East-West divide in the drug's availability.

Approval in Japan (PMDA)

In January 2021, Japan's Ministry of Health, Labour and Welfare, acting on the recommendation of the Pharmaceuticals and Medical Devices Agency (PMDA), granted manufacturing and marketing approval for Anamorelin.[6]

• Decision: Anamorelin was approved for the indication of "cancer cachexia in the following malignant tumors: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer".[8]
• Rationale: The PMDA's review concluded that Anamorelin demonstrated efficacy in the treatment of cancer cachexia and possessed an acceptable safety profile.[6] The agency placed significant weight on the drug's proven ability to increase LBM and improve appetite-related quality of life, as demonstrated in Japanese clinical studies (ONO-7643-04 and -05).[6] In the context of a disease with no other approved pharmacological treatments, the PMDA determined that these benefits had "a certain clinical significance for patients with cancer cachexia".[6] This decision reflects a regulatory philosophy that prioritizes making a first-in-class treatment available for a condition with high unmet medical need, even if the benefits are focused on body composition and symptoms rather than functional outcomes.
• Conditions for Approval: The approval was not unconditional. It came with strict requirements for a robust Risk Management Plan and a mandatory, all-case post-marketing surveillance study to continue gathering data on the drug's real-world safety and efficacy.[6]

Refusal in Europe (EMA)

In stark contrast, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the refusal of marketing authorisation for Anamorelin in May 2017. This negative opinion was confirmed after a re-examination process in September 2017.[14]

• Decision: Marketing authorisation was refused for the proposed indication of treating anorexia, cachexia, or unintended weight loss in patients with NSCLC.[14]
• Rationale: The CHMP's refusal was based on a critical assessment of the risk-benefit balance, which they concluded was negative. Their reasoning centered on three key points [14]:

1. Marginal Efficacy: The committee viewed the statistically significant increase in LBM as a "marginal effect" and not sufficiently robust to be considered a primary clinical benefit on its own.
2. Lack of Functional Benefit: The failure of the ROMANA trials to meet the co-primary endpoint of HGS was a decisive factor. The CHMP concluded there was "no proven effect on hand grip strength or patients' quality of life," arguing that an increase in muscle mass without a corresponding improvement in function was not a clinically meaningful outcome for patients.
3. Inadequate Safety Data: The EMA's assessment was further complicated by concerns that arose from an inspection of clinical study sites. The committee stated that "safety data on the medicine had not been recorded adequately," which prevented a thorough evaluation of potential risks and undermined confidence in the overall safety database.

• Conclusion: Based on these factors, the CHMP was of the opinion that the benefits of Anamorelin did not outweigh its risks, leading to the refusal.[14]

Status in the United States (FDA) and Future Outlook

Anamorelin is not approved by the U.S. Food and Drug Administration (FDA) and remains an investigational drug in the United States.[2] While some clinical trials may offer expanded access, there is no approved indication.[52] One U.S.-based trial (NCT01767857) that used survival as a primary endpoint was terminated early for futility, highlighting the difficulty in demonstrating benefits on hard outcomes.[2] Gaining approval in the U.S. and Europe would likely require new clinical trials designed to demonstrate a clear and convincing benefit on a functional or patient-reported outcome endpoint that is accepted by these agencies as being clinically meaningful.[48]

Table 5: Comparative Summary of Regulatory Decisions: PMDA vs. EMA

Assessment Criterion	PMDA Rationale / Interpretation	EMA Rationale / Interpretation
Assessment of LBM Benefit	Viewed as a clinically significant outcome, demonstrating efficacy in a disease with no approved treatments.	Considered a "marginal effect" and insufficient as a primary benefit without accompanying functional improvement.
Assessment of Functional Benefit (HGS)	Acknowledged the lack of effect but did not consider it a barrier to approval, given the positive LBM and appetite data.	The failure to improve HGS was a critical deficiency, indicating a lack of clinically meaningful patient benefit.
View on Patient QOL / Symptoms	Considered the improvement in appetite-related QOL to be a meaningful component of the drug's efficacy.	Concluded there was "no proven effect on patients' quality of life."
Stance on Unmet Medical Need	The high unmet need for a CACS treatment was a significant factor supporting approval of a first-in-class agent.	While the unmet need was acknowledged, it did not override the concerns about the drug's modest efficacy and data integrity.
Final Decision & Conditions	Approved with mandatory post-marketing surveillance and a risk management plan.	Refused due to a negative risk-benefit assessment.

The case of Anamorelin serves as a landmark example of how differing regulatory philosophies can lead to opposite outcomes based on the same fundamental clinical data. The PMDA's decision suggests a framework that may be more flexible in accepting surrogate endpoints like LBM, particularly for first-in-class drugs in areas of high unmet need. Their approval indicates a belief that halting muscle loss and improving appetite are valuable interventions in their own right. In contrast, the EMA's refusal reflects a stricter, more patient-centric definition of clinical benefit, demanding that any physiological change (like increased LBM) must translate into a tangible improvement that a patient can feel or use, such as increased strength or better overall quality of life. The additional concerns regarding data recording from site inspections further solidified the EMA's cautious stance. This divergence provides a critical lesson for drug developers in the CACS space: success in the modern regulatory landscape, particularly in the West, requires not only demonstrating a biological effect but also proving that this effect delivers a meaningful and measurable benefit to the patient.

Synthesis and Expert Conclusion

Anamorelin stands as a significant and pioneering agent in the challenging field of supportive oncology. It is a pharmacologically well-designed molecule with a clear and targeted mechanism of action that successfully mimics the dual anabolic and orexigenic functions of ghrelin. Clinical data from the comprehensive ROMANA program have unequivocally shown that Anamorelin can increase lean body mass, total body weight, and appetite in patients suffering from cancer anorexia-cachexia syndrome.[13] Its approval in Japan marked a historic milestone, providing the first-ever approved pharmacotherapy for this debilitating condition and offering a new therapeutic option for a patient population with a profound unmet need.[8]

However, the drug's development journey is defined by its central, unresolved challenge: the disconnect between anabolic gain and functional improvement. The consistent failure of Anamorelin to improve handgrip strength in its pivotal trials remains the primary limitation of the drug and the crux of its regulatory failure in Europe and its investigational status in the United States.[13] This finding has reshaped the scientific understanding of cachexia, suggesting that reversing muscle mass loss, while necessary, may not be sufficient to restore physical function in the complex metabolic and inflammatory milieu of advanced cancer.

When placed in the context of other pharmacological options for CACS, Anamorelin offers a distinct advantage. Unlike megestrol acetate, which primarily increases fat mass, or corticosteroids, which are limited by short-term efficacy and significant long-term toxicities, Anamorelin provides a targeted anabolic stimulus that preferentially builds lean tissue.[31] Nevertheless, its own safety profile is not without concerns. The predictable risk of hyperglycemia and the emerging signal for cardiac conduction abnormalities necessitate careful patient monitoring and risk management, as mandated by the conditions of its Japanese approval.[48]

The future of Anamorelin outside of Asia remains uncertain. Any path toward approval in Western markets will almost certainly require new clinical evidence from trials designed with co-primary endpoints that can successfully link the drug's anabolic effects to a clear, clinically meaningful improvement in physical function or quality of life. More broadly, the story of Anamorelin will have a lasting impact on the entire field of CACS drug development. It has validated the stimulation of the ghrelin-GH-IGF-1 axis as a viable therapeutic strategy and has established the measurement of LBM as a key endpoint. At the same time, it has elevated the standard for approval by demonstrating that functional outcomes are now considered indispensable by major regulatory bodies. The path forward for treating cancer cachexia will likely not be with a single agent, but rather through multi-modal strategies that combine anabolic agents like Anamorelin with complementary interventions such as structured exercise, targeted nutritional support, and anti-inflammatory therapies.[48] Only through such a holistic approach can the field hope to achieve the comprehensive, patient-centric benefits that are now the benchmark for therapeutic success.

Works cited

1. Anamorelin | C31H42N6O3 | CID 9828911 - PubChem, accessed September 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Anamorelin
2. What's Next After Anamorelin? - PMC, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5776683/
3. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia | DDDT - Dove Medical Press, accessed September 24, 2025, https://www.dovepress.com/anamorelin-hydrochloride-in-the-treatment-of-cancer-anorexia-cachexia--peer-reviewed-fulltext-article-DDDT
4. (PDF) Oncology Update: Anamorelin - ResearchGate, accessed September 24, 2025, https://www.researchgate.net/publication/319214628_Oncology_Update_Anamorelin
5. An open-label clinical trial of the effects of age and gender on the ..., accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4657463/
6. Report on the Deliberation Results December 11, 2020 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental - PMDA, accessed September 24, 2025, https://www.pmda.go.jp/files/000242929.pdf
7. Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions | Anticancer Research, accessed September 24, 2025, https://ar.iiarjournals.org/content/45/3/865
8. ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan, accessed September 24, 2025, https://www.ono-pharma.com/en/news/20210122.html
9. ar.iiarjournals.org, accessed September 24, 2025, https://ar.iiarjournals.org/content/45/3/865#:~:text=In%20preclinical%20studies%20(in%20vitro,25)%20(Figure%201).
10. What is the mechanism of Anamorelin Hydrochloride? - Patsnap Synapse, accessed September 24, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-anamorelin-hydrochloride
11. Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study - Spandidos Publications, accessed September 24, 2025, https://www.spandidos-publications.com/10.3892/mco.2025.2858
12. Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2 - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39992021/
13. Anamorelin in patients with non-small-cell lung cancer and cachexia ..., accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/26906526/
14. Adlumiz | European Medicines Agency (EMA), accessed September 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/adlumiz
15. Anamorelin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB06645
16. Anamorelin hydrochloride in the treatment of cancer anorexia ..., accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5557912/
17. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile - PMC - PubMed Central, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4248409/
18. Anamorelin Hydrochloride | C31H43ClN6O3 | CID 16072155 - PubChem, accessed September 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Anamorelin-hydrochloride
19. anamorelin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 24, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=14127
20. Anamorelin (RC-1291) | Ghrelin Receptor Agonist - MedchemExpress.com, accessed September 24, 2025, https://www.medchemexpress.com/Anamorelin.html
21. Exploring Metabolic Pathways of Anamorelin, a Selective Agonist of the Growth Hormone Secretagogue Receptor, via Molecular Networking - MDPI, accessed September 24, 2025, https://www.mdpi.com/1999-4923/15/12/2700
22. Anamorelin | CAS 249921-19-5 | SCBT - Santa Cruz Biotechnology, accessed September 24, 2025, https://www.scbt.com/p/anamorelin-249921-19-5
23. Anamorelin = 98 HPLC 249921-19-5 - Sigma-Aldrich, accessed September 24, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml2519
24. Anamorelin (RC-1291, CAS Number: 249921-19-5) | Cayman Chemical, accessed September 24, 2025, https://www.caymanchem.com/product/24676/anamorelin
25. Anamorelin | CAS NO.:249921-19-5 - GlpBio, accessed September 24, 2025, https://www.glpbio.com/anamorelin.html
26. Compound: ANAMORELIN HYDROCHLORIDE (CHEMBL2103794) - ChEMBL - EMBL-EBI, accessed September 24, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2103794
27. Pharmacodynamic hormonal effects of anamorelin, a novel oral ..., accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/19196529/
28. Anamorelin for cancer cachexia, accessed September 24, 2025, https://access.portico.org/Portico/show?viewFile=pdf&auId=pjb7bbkdc0r
29. Anamorelin - Wikipedia, accessed September 24, 2025, https://en.wikipedia.org/wiki/Anamorelin
30. A Systematic Review and Meta-Analysis of the Clinical Use of Megestrol Acetate for Cancer-Related Anorexia/Cachexia - MDPI, accessed September 24, 2025, https://www.mdpi.com/2077-0383/11/13/3756
31. The Anorexia-Cachexia Syndrome: Pharmacologic Management ..., accessed September 24, 2025, https://www.mypcnow.org/fast-fact/the-anorexia-cachexia-syndrome-pharmacologic-management/?print=print
32. Megestrol Acetate for Cancer Anorexia/Cachexia - Palliative Care Network of Wisconsin, accessed September 24, 2025, https://www.mypcnow.org/fast-fact/megestrol-acetate-for-cancer-anorexia-cachexia/?print=print
33. Effects of strong cytochrome P450 (CYP)3A4 inducers/inhibitors on the pharmacokinetic (PK) profile of anamorelin in healthy volunteers. - ASCO Publications, accessed September 24, 2025, https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e22180
34. What is Anamorelin Hydrochloride used for? - Patsnap Synapse, accessed September 24, 2025, https://synapse.patsnap.com/article/what-is-anamorelin-hydrochloride-used-for
35. Anamorelin: Ghrelin Receptor Agonism as a Potential Intervention for Osteosarcopenia | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed September 24, 2025, https://academic.oup.com/jcem/article/109/9/e1804/7585686
36. (PDF) The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers - ResearchGate, accessed September 24, 2025, https://www.researchgate.net/publication/348107876_The_regulatory_approval_of_anamorelin_for_treatment_of_cachexia_in_patients_with_non-small_cell_lung_cancer_gastric_cancer_pancreatic_cancer_and_colorectal_cancer_in_Japan_facts_and_numbers
37. Anamorelin Completed Phase 2 Trials for Cancer Cachexia (CC) Treatment - DrugBank, accessed September 24, 2025, https://go.drugbank.com/drugs/DB06645/clinical_trials?conditions=DBCOND0161448&phase=2&purpose=treatment&status=completed
38. ROMANA 3: a phase 3 safety extension study of anamorelin in ..., accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5834076/
39. A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3. - ASCO, accessed September 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT147675
40. Study Details | NCT01387282 | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2), accessed September 24, 2025, https://clinicaltrials.gov/study/NCT01387282
41. Promising cancer drug for Cachexia rejected by CHMP - Clinical Trials Arena, accessed September 24, 2025, https://www.clinicaltrialsarena.com/comment/commentpromising-cancer-drug-cachexia-rejected-by-chmp-5885402/
42. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia - Oxford Academic, accessed September 24, 2025, https://academic.oup.com/jcem/article/109/3/e945/7459801
43. Sarcopenia Completed Phase 1 Trials for Anamorelin (DB06645) | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/indications/DBCOND0003759/clinical_trials/DB06645?phase=1&status=completed
44. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia | Request PDF - ResearchGate, accessed September 24, 2025, https://www.researchgate.net/publication/376305429_Effect_of_anamorelin_a_ghrelin_receptor_agonist_on_muscle_and_bone_in_adults_with_osteosarcopenia
45. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/38057159/
46. What are the side effects of Anamorelin Hydrochloride? - Patsnap Synapse, accessed September 24, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-anamorelin-hydrochloride
47. Emerging Treatment Options For Cancer-Associated Cachexia: A ..., accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6825473/
48. The regulatory approval of anamorelin for treatment of cachexia in ..., accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7890143/
49. Anamorelin and Conduction Defects: A Literature Review and Analysis of the Japanese Pharmacovigilance Database - PMC - PubMed Central, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11705112/
50. Real‐world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post‐marketing surveillance in Japan - PubMed Central, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11063721/
51. Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride) - European Medicines Agency, accessed September 24, 2025, https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_en.pdf
52. Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | ClinicalTrials.gov, accessed September 24, 2025, https://www.clinicaltrials.gov/study/NCT03637816?term=ANAMORELIN&viewType=Table&rank=2
53. Study Details | NCT03637816 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer, accessed September 24, 2025, https://www.clinicaltrials.gov/study/NCT03637816
54. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia - Mayo Clinic, accessed September 24, 2025, https://mayoclinic.elsevierpure.com/en/publications/randomized-comparison-of-megestrol-acetate-versus-dexamethasone-v
55. The Latest Treatments for Cancer Cachexia: An Overview ..., accessed September 24, 2025, https://ar.iiarjournals.org/content/43/2/511